CN1258536C - Pineapple anhydride compound and its use - Google Patents

Pineapple anhydride compound and its use Download PDF

Info

Publication number
CN1258536C
CN1258536C CN 200410009056 CN200410009056A CN1258536C CN 1258536 C CN1258536 C CN 1258536C CN 200410009056 CN200410009056 CN 200410009056 CN 200410009056 A CN200410009056 A CN 200410009056A CN 1258536 C CN1258536 C CN 1258536C
Authority
CN
China
Prior art keywords
pineapple
ananasoside
anhydride compound
blood flow
anhydride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN 200410009056
Other languages
Chinese (zh)
Other versions
CN1569883A (en
Inventor
王伟
杜力军
丁怡
邢东明
王如峰
马超
王雪莉
陈芸芸
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsinghua University
Original Assignee
Tsinghua University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsinghua University filed Critical Tsinghua University
Priority to CN 200410009056 priority Critical patent/CN1258536C/en
Publication of CN1569883A publication Critical patent/CN1569883A/en
Application granted granted Critical
Publication of CN1258536C publication Critical patent/CN1258536C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to a pineapple anhydride compound and a usage thereof, particularly to a new pineapple anhydride compound extracted from pineapple leaves and a usage in medical treatment. Pharmacological experiments show that pineapple anhydride has the functions of resisting oxidation and enhancing cerebral blood; the present invention can be used for treating peroxide raising and diseases resulting from the peroxide raising and can be used for diseases of cerebral ischemia, cranial nerve damage, etc., such as apoplexy, lipid metabolism disorder, etc.

Description

Pineapple anhydride compound and uses thereof
Technical field
The present invention relates to the pineapple anhydride compound of one group of novelty and the purposes aspect medical thereof, be the pineapple anhydride compound that from pineapple leaves, separates the novelty of preparation specifically, and the application of this compound in the rising of preparation treatment body endoperoxide, oxidized low-density and high-density lipoprotein (HDL) raise caused multiple disease medicament.
Background technology
Pineapple is bromelia pineapple Ananas comosus (L.) Merr.[Bromelia comosa L.; A.sativusSchult.Et Schult.f.] fruit, claim pineapple again.Originate in America, existing extensively planting in the torrid areas, all there is plantation on ground such as China Fujian, Guangdong, Hainan, Guangxi, Yunnan.This product beginning is stated from clearly. and Wu Qirui " An Illustrated Book on Plants ", run after fame to reveal pocket.This secretary is carried: " reveal pocket and produce Guangdong, a POLO is given birth between hill, and is real in radish, the acropetal leaf cluster, and the long dark tooth of point, flavor look fragrant tool is good.The ripe golden yellow of fruit, Pi Jian such as fish scale shape, peeling food meat, fragrant and sweet no slag, June is ripe ".
Ancient times does not have clearly record for pineapple leaves, the raw material that modern people arghan commonly used is braiding and papermaking (" the Chinese Higher plant illustrated handbook. the 5th " Science Press 1976).Pineapple leaves on the books has and helps digestion and stomach when near, and the antidiarrheic effect cures mainly summer heat and rushes down, maldigestion, gastral cavilty distending pain etc. (" China's book on Chinese herbal medicine. the 8th volume " Shanghai science tech publishing house 1999).
Pineapple leaves is more rare as medicinal record, the effect of diseases such as the pineapple leaves of especially not appearing in the newspapers or pineapple acid glycosides and new compound pineapple acid glycosides treatment body endoperoxide thereof are too much, cerebral ischemia.
Summary of the invention
The purpose of this invention is to provide one group of new pineapple anhydride compound and the purposes aspect medical thereof with pharmaceutical use.
Its general structure of pineapple anhydride compound specifically provided by the invention is shown in (I):
Wherein:
Ananasoside A: R1=O-β-D-xyl R2=OH R3=H, H R4=OH
Ananasoside B: R1=O-β-D-glu (6 → 1) glu R2=H, H R3=OH R4=H, H
Physico-chemical property and the various wave spectrum feature thereof of above-mentioned new pineapple anhydride compound A-B are as follows:
Ananasoside A (ananasoside A, 3 β, 11a, 15a-trihydroxycycloart-24-en-26-oic acid-3-O-β-D-xylopyra-noside);
Colourless unformed solid, mp158-160 ℃;
[a] 25D-150°(c 0.10，MeOH)；
UV(MeOH)nm：203；
IR v max(KBr)cm -1：3376，2936，1691，1254，1066，991，862；
HRFABMS m/z 638.4277[M+NH 4] +(molecular formula C 35H 56O 9);
1H NMR, DEPT and 13C NMR (pyridine-d 5) data are as follows.
The nuclear magnetic resonance data of Ananasoside A:
No. 1H 13C DEPT
1 1.35(1H，m)，1.66(1H，m) 32.8 CH 2
2 1.76(1H，m)，2.39(1H，m) 31.1 CH 2
3 3.81(1H，dd，3.5，11Hz) 88.7 CH
4 42.1 C
5 1.44(1H，dd，4.5，11.5Hz) 48.0 CH
6 1.30(1H，m)，1.44(1H，m) 21.7 CH 2
7 2.38(2H，d，12.5Hz) 30.2 CH 2
8 1.76(1H，m) 42.1 CH
9 20.6 C
10 26.2 C
11 1.44(1H，dd，9.0，12.OHz)，1.76(1H，m) 26.2 CH 2
12 4.12(1H，t，12.0，6.OHz) 73.7 CH
13 49.9 C
14 53.0 C
15 4.01(1H，d，8.0) 77.2 CH
16 1.95(1H，m)，2.45(1H，m) 40.2 CH 2
17 2.79(1H，m) 44.1 CH
18 1.58(3H，s) 18.1 CH 3
19 0.43(1H，d，3.5)，0.65(1H，d，3.5) 30.3 CH 2
20 1.81(1H，m) 36.8 CH
21 1.36(3H，s) 18.1 CH 3
22 1.82(2H，m) 35.6 CH 2
23 1.36(2H，m) 26.2 CH 2
24 7.25(1H，t，6.5，15Hz) 142.7 CH
25 128.8 C
26 170.6 C
27 2.09(3H，s) 12.8 CH 2
28 1.30(3H，s) 25.8 CH 3
29 1.04(3H，s) 15.4 CH 3
30 1.33(3H，s) 20.6 CH 3
1′ 4.82(1H，d，6.5Hz) 107.4 CH
2′ 4.45(1H，m) 72.9 CH
3′ 4.18(1H，dd，9.OHz) 74.6 CH
4′ 4.33(1H.m) 69.5 CH
5′ 3.81(2H，d，11.5Hz) 66.7 CH 2
Ananasoside B (ananasoside B, 3 β, 16 β-trihydroxycycloart-24-en-26-oicacid-3-O-β-D-glucopyrano-side (6 → 1) glu;
Colourless unformed solid, mp 211-213 ℃;
[a] 25D-93°(c 0.16，MeOH)；
UV(MeOH)nm：215；
IR v max(KBr)cm -1：3406，2937，1691，1383，1077，1041，892；
HRFABMS m/z 814.4967[M+NH 4] +(molecular formula C 42H 68O 14);
1H NMR, DEPT and 13C NMR (pyridine-d 5) data are as follows.
The nuclear magnetic resonance data of Ananasoside B:
No. 1H 13C DEPT
1 1.56(1H，m)，1.76(1H，m) 33.2 CH 2
2 1.08(1H，m)，1.46(1H，m) 32.1 CH 2
3 3.47(1H，dd，3.5，11Hz) 88.8 CH
4 41.3 C
5 1.46(1H，dd，12.5，4.5Hz) 47.6 CH
6 1.38(1H，m)，1.56(1H，m) 20.0 CH 2
7 1.15(1H，m)，1.90(1H，m) 30.0 CH 2
8 1.48(1H，m) 47.0 CH
9 20.3 C
10 25.8 C
11 1.49(1H，m)，2.01(1H，m) 26.8 CH 2
12 1.66(2H，m) 32.9 CH 2
13 48.0 C
14 47.9 C
15 1.30(1H，m) 48.6 CH 2
16 4.28(1H，d，8.OHz) 78.0 CH
17 1.96(1H，m) 61.6 CH
18 1.10(3H.s) 18.8 CH 3
19 0.22(1H，d，3.5Hz)，0.51(1H，d，3.5Hz) 30.0 CH 2
20 1.31(1H，m) 35.0 CH
21 0.93(3H，s) 18.6 CH 3
22 0.86(1H，m)，1.80(1H，m) 35.1 CH 2
23 1.01(1H，m)，1.69(1H，m) 26.2 CH 2
24 7.30(1H，t，6.5，15Hz) 143.0 CH
25 128.8 C
26 170.6 C
27 2.13(3H，s) 12.8 CH 3
28 1.35(3H，s) 26.8 CH 3
29 1.26(3H，s) 15.4 CH 3
30 1.35(3H，s) 21.2 CH 3
1′；1″ 4.95(1H，d，8.0Hz)；5.39(1H，d，7.5Hz) 104.9 CH
106.1
2′；2″ 4.20-4.36(m) 83.5 76.0 CH
3′；3″ 4.20-4.36(m) 76.8 77.1 CH
4′；4″ 4.20-4.36(m) 71.5 71.7 CH
5′；5″ 4.20-4.36(m) 78.2 78.3 CH
6′；6″ 4.60(2H，dd，12Hz)；4.60(2H，dd，12Hz) 62.8 62.8 CH 2
The application of pineapple anhydride compound provided by the invention in the medicine of the disease for preparing the endoperoxide rising of treatment body and cause thus.
The application of pineapple anhydride compound provided by the invention in the former impaired medicine of preparation treatment cerebral ischemia and the cranial nerve that causes thus.
Described compound can be independent application during as drug use, also can be to mix use with other composition.
When clinical application,, use separately or prepare the medicine of operable various different dosage forms clinically with other drug with the preparation process of routine.As powder, pill, capsule, tablet, microcapsule, soft capsule, film, suppository, injection, paste, tincture, powder, electuary, aerosol, various external preparations etc.
In years of researches, the inventor separates the compound of preparing---Ananasoside A and Ananasoside B from pineapple leaves.Pharmacological evaluation shows that pineapple acid glycosides has anti-oxidant, strengthens the effect of cerebral blood flow, can be used for treating the body endoperoxide and raise and illness that cerebral ischemia causes, as apoplexy, lipid metabolism is disorderly etc.Experimental result shows that pineapple acid glycosides has the effect of tangible rising cerebral blood flow, and effectively final concentration is 2.5-10mg/kg.Experiment in vitro shows that pineapple acid glycosides has the effect that suppresses to lack sugared anoxic cerebral tissue MDA generation strongly, and minimal effective concentration is 1 * 10 -6G/ml.
Description of drawings
Fig. 1 is the chemical structural formula of pineapple anhydride compound provided by the invention.
Embodiment
5～10 times alcoholic solvent with medicinal material weight heats extraction under 50 ℃～90 ℃ earlier, obtains extracting solution; Behind concentrating under reduced pressure under 50～90 ℃ of temperature, with 2～5 times of water dissolution of medicinal material weight, centrifugal or static filtration discards precipitation, gets supernatant liquor with extracting solution; With supernatant liquor by macroporous adsorbent resin, first water wash-out, elutriant is discarded, uses concentration greater than 70% ethanol elution again, at 50～90 ℃ of following concentrating under reduced pressure of temperature, drying under reduced pressure or lyophilize then obtains the pineapple leaves extract with elutriant; The pineapple leaves extract is dissolved with alcohol solvent, recycle silicon glue is mixed sample, separates with silica gel column chromatography, uses chloroform: methyl alcohol or sherwood oil: acetone or chloroform: the acetone gradient elution, successively, can successively obtain this compound-Ananasoside A and Ananasoside B with reverse phase silica gel and dextrane gel purifying.
Pineapple acid villous themeda separates the source plant of preparation, can be pineapple leaves, also comprises other any plant.
Following drug study data is confirmed preparation of the said pineapple acid of the present invention glycosides and uses thereof, should not regard the following example as limitation of the present invention again simultaneously.
Embodiment 1
The separation preparation of Ananasoside A and physics and chemistry and spectral data:
When preparation has above-mentioned new compound, at first at 50% alcohol pineapple leaves is extracted 3 times 60 ℃ of heating with 5 times of concentration of medicinal material weight, be 1 hour at every turn, obtain extracting solution; Extracting solution is in decompression (pressure 98Kpa) then, temperature 50 ℃ concentrate after, with 2 times of water dissolution of medicinal material weight, centrifugal, discard precipitation, supernatant liquor passes through macroporous adsorbent resin, first water wash-out, and elutriant is discarded, use 80% ethanol elution again, elutriant is 50 ℃ of (pressure 98Kpa) concentrating under reduced pressure in temperature, and enriched material decompression (pressure 98Kpa) drying obtains the pineapple leaves extract.Pineapple leaves extract 70% dissolve with ethanol, recycle silicon glue is mixed sample, separates with silica gel column chromatography, uses chloroform: the methyl alcohol gradient elution, separate with reverse phase silica gel earlier, continue and use the dextrane gel purifying, obtain Ananasoside A.
Ananasoside A (ananasoside A, 3 β, 11a, 15a-trihydroxycycloart-24-en-26-oic acid-3-O-β-D-xylopyra-noside);
Colourless unformed solid, mp158-160 ℃;
[a] 25D-150°(c 0.10，MeOH)；
UV(MeOH)nm：203；
IR v max(KBr)cm -1：3376，2936，1691，1254，1066，991，862；
HRFABMS m/z 638.4277[M+NH 4] +(molecular formula C 35H 56O 9);
1H NMR, DEPT and 13C NMR (pyridine-d 5) data see following table 1.
The nuclear magnetic resonance data of table 1 Ananasoside A
No. 1H 13C DEPT
1 1.35(1H，m)，1.66(1H，m) 32.8 CH 2
2 1.76(1H，m)，2.39(1H，m) 31.1 CH 2
3 3.81(1H，dd，3.5，11Hz) 88.7 CH
4 42.1 C
5 1.44(1H，dd，4.5，11.5Hz) 48.0 CH
6 1.30(1H，m)，1.44(1H，m) 21.7 CH 2
7 2.38(2H，d，12.5Hz) 30.2 CH 2
8 1.76(1H，m) 42.1 CH
9 20.6 C
10 26.2 C
11 1.44(1H，dd，9.0，12.OHz)，1.76(1H，m) 26.2 CH 2
12 4.12(1H，t，12.0，6.OHz) 73.7 CH
13 49.9 C
14 53.0 C
15 4.01(1H，d，8.0) 77.2 CH
16 1.95(1H，m)，2.45(1H，m) 40.2 CH 2
17 2.79(1H，m) 44.1 CH
18 1.58(3H，s) 18.1 CH 3
19 0.43(1H，d，3.5)，0.65(1H，d，3.5) 30.3 CH 2
20 1.81(1H，m) 36.8 CH
21 1.36(3H，s) 18.1 CH 3
22 1.82(2H，m) 35.6 CH 2
23 1.36(2H，m) 26.2 CH 2
24 7.25(1H，t，6.5，15Hz) 142.7 CH
25 128.8 C
26 170.6 C
27 2.09(3H，s) 12.8 CH 3
28 1.30(3H，s) 25.8 CH 3
29 1.04(3H，s) 15.4 CH 3
30 1.33(3H，s) 20.6 CH 3
1′ 4.82(1H，d，6.5Hz) 107.4 CH
2′ 4.45(1H，m) 72.9 CH
3′ 4.18(1H，dd，9.OHz) 74.6 CH
4′ 4.33(1H，m) 69.5 CH
5′ 3.81(2H，d，11.5Hz) 66.7 CH 2
Embodiment 2
The separation preparation of Ananasoside B and physics and chemistry and spectral data:
When preparation had above-mentioned new compound, extracting solution was in decompression (pressure 98Kpa) then, temperature 70 ℃ concentrate after, 2 times of water dissolution with medicinal material weight, centrifugal, discard precipitation, supernatant liquor passes through macroporous adsorbent resin, elder generation's water wash-out, elutriant is discarded, uses 80% ethanol elution again, and elutriant is 70 ℃ of (pressure 98Kpa) concentrating under reduced pressure in temperature, enriched material decompression (pressure 98Kpa) drying obtains the pineapple leaves extract.Pineapple leaves extract 50% dissolve with ethanol, recycle silicon glue is mixed sample, separates with silica gel column chromatography, uses chloroform: the acetone gradient elution, separate with reverse phase silica gel earlier, continue and use the dextrane gel purifying, behind Ananasoside A, obtain Ananasoside B.
Ananasoside B (ananasoside B, 3 β, 16 β-trihydroxycycloart-24-en-26-oicacid-3-O-β-D-glucopyrano-side (6 → 1) glu;
Colourless unformed solid, mp 211-213 ℃;
[a] 25D-93°(c 0.16，MeOH)；
UV(MeOH)nm：215；
IR v max(KBr)cm -1：3406，2937，1691，1383，1077，1041，892；
HRFABMS m/z 814.4967[M+NH 4] +(molecular formula C 42H 68O 14);
1H NMR, DEPT and 13C NMR (pyridine-d 5) data see following table 2.
The nuclear magnetic resonance data of table 2 Ananasoside B
No. 1H 13C DEPT
1 1.56(1H，m)，1.76(1H，m) 33.2 CH 2
2 1.08(1H，m)，1.46(1H，m) 32.1 CH 2
3 3.47(1H，dd，3.5，11Hz) 88.8 CH
4 41.3 C
5 1.46(1H，dd，12.5，4.5Hz) 47.6 CH
6 1.38(1H，m)，1.56(1H，m) 20.0 CH 2
7 1.15(1H，m)，1.90(1H，m) 30.0 CH 2
8 1.48(1H，m) 47.0 CH
9 20.3 C
10 25.8 C
11 1.49(1H，m)，2.01(1H，m) 26.8 CH 2
12 1.66(2H，m) 32.9 CH 2
13 48.0 C
14 47.9 C
15 1.30(1H，m) 48.6 CH 2
16 4.28(1H，d，8.0Hz) 78.0 CH
17 1.96(1H，m) 61.6 CH
18 1.10(3H，s) 18.8 CH 3
19 0.22(1H，d，3.5Hz)，0.51(1H，d，3.5Hz) 30.0 CH 2
20 1.31(1H，m) 35.0 CH
21 0.93(3H，s) 18.6 CH 3
22 0.86(1H，m)，1.80(1H，m) 35.1 CH 2
23 1.01(1H，m)，1.69(1H，m) 26.2 CH 2
24 7.30(1H，t，6.5，15Hz) 143.0 CH
25 128.8 C
26 170.6 C
27 2.13(3H，s) 12.8 CH 3
28 1.35(3H，s) 26.8 CH 3
29 1.26(3H，s) 15.4 CH 3
30 1.35(3H，s) 2L 2 CH 3
1′；1″ 4.95(1H，d，8.0Hz)；5.39(1H，d，7.5Hz) 104.9 CH
106.1
2′；2″ 4.20-4.36(m) 83.5 76.0 CH
3′；3″ 4.20-4.36(m) 76.8 77.1 CH
4′；4″ 4.20-4.36(m) 71.5 71.7 CH
5′；5″ 4.20-4.36(m) 78.2 78.3 CH
6′；6″ 4.60(2H，dd，12Hz)；4.60(2H，dd，12Hz) 62.8 62.8 CH 2
Embodiment 3: to the effect of mouse meninx volume of blood flow
Observe Ananasoside A of the present invention, B is to the effect of mouse meninx volume of blood flow.Ananasoside A, B.Time spent is mixed with desired concn with physiological saline.Experimental animal is male ICR kind mouse, non-inbred lines closed colony, and body weight 18-22g is provided by Beijing dimension tonneau China Experimental Animal Center.Laboratory room temperature 20-22 ℃, relative humidity 40%～60%, the ventilator ventilation, lamp 12h/ day, raise in cages, 5 in every cage, per three days cleaning cage houses are once.
After getting mouse urethane (1.0g/kg) anesthesia, fixing head cuts skin, in the motor area of cerebral cortex (AP -1, L 2) settle laser probe (JI-200 laser microcirculation instrument, Tianjin Nankai University produces), treat stablize after 5-10 minute and begin to test cerebral blood flow, the variation of record administration front and back meninx volume of blood flow.
This experimental observation index and index are expressed: measured result is directly through the JI-200 software processes, and the meninx volume of blood flow is with KHz (kilohertz) expression, and the meninx volume of blood flow increases percentage value [volume of blood flow before=(the preceding volume of blood flow of volume of blood flow-administration after the administration)/administration].
This dosage of testing used Ananasoside A and Ananasoside B is respectively 2.5mg/kg, 10mg/kg; Route of administration is the tail intravenously administrable; The administration volume is the 0.1ml/10g mouse.
This test blank is an equal-volume physiological saline, and the positive drug contrast is epinephrine inj, 10mg/ml.Shanghai Tian Feng pharmaceutical factory produces, lot number: 020601, and the mouse consumption is 0.01mg/kg.
This testing data is all with the Excel software processes.
Table 3: Ananasoside A, B is to the effect of normal mouse brain volume of blood flow (x ± s)
Medicine Dosage (mg/kg) Cerebral blood flow (CBF) (KHz)
0 1 3 5 10 15 (minute)
Control group adrenaline Ananasoside A Ananasoside A Ananasoside B Ananasoside B 0.01 2.5 10 2.5 10 11.67 ±4.02 12.13 ±1.77 9.0± 1.76 10.07 ±1.94 12.87 ±3.63 10.07 ±1.94 11.51 ±4.31 11.04 ±1.72 9.09 ±1.63 11.03 ±1.69 13.26 ±3.68 11.03 ±1.69 11.29 ±3.76 13.06 ±1.32 9.16 ±1.73 10.94 ±2.12 13.49 ±3.75 10.94 ±2.12 11.72 ±4.17 13.09 ±1.41 9.39 ±1.89 11.16 ±2.33 13.69 ±3.51 11.16 ±2.33 11.77 ±3.92 13.57 ±1.43 9.55 ±1.78 11.31 ±2.32 13.76 ±3.74 11.31 ±2.32 11.78 ±3.96 13.0 ±1.36 9.42 ±2.03 11.51 ±2.32 13.85 ±3.64 11.51 ±2.32
With compare P＞0.05 with the time control group.n＝5
Table 4: Ananasoside A, B increases percent value (x ± s) to normal mouse brain volume of blood flow
Medicine Dosage (mg/kg) Cerebral blood flow (CBF) increases percent value (%)
0 1 3 5 10 15 (minute)
Control group adrenaline Ananasoside A Ananasoside A Ananasoside B Ananasoside B 0.01 2.5 10 2.5 10 0 0 0 0 0 0 -2.0± 5.46 -8.7± 2.97 1.33± 1.94 10.48± 10.42* 3.59± 8.79 10.47± 10.42* -3.01± 4.37 9.08± 16.33* 1.85± 2.53 8.81± 9.45* 5.04± 4.26* 8.81± 9.45* 0.13± 3.25 9.58± 17.98 4.16± 2.87* 10.77± 9.11* 7.18± 7.69 10.77± 9.11* 1.18± 3.31 12.52± 6.46* 6.32± 3.65* 12.31± 8.79* 7.22± 6.79 12.31± 8.79* 1.17± 4.07 7.87± 8.07 4.3± 5.65 14.64± 12.45* 8.19± 8.32 14.64± 12.45*
With compare * P＜0.05, * * P＜0.01 with the time control group.n＝5
Experimental result shows, the effect that Ananasoside A-B is significantly increased mouse meninx volume of blood flow.Generally promptly had cerebral blood flow to raise after administration in 1 minute, cerebral blood flow raise obviously in 5-15 minute; Show that Ananasoside A-B has directly dilating effect to the cerebrovascular, prompting has better action for cerebral ischemia and the caused disease of vascular spasm thereof.
Embodiment 4: to the influence of brain MDA generation
Observe the restraining effect that pineapple acid glycosides of the present invention generates mouse brain MDA.Used Ananasoside A of the present invention and Ananasoside B.Time spent is mixed with desired concn with physiological saline.Testing used animal is male ICR mouse, non-inbred lines closed colony, and Beijing Vital River Experimental Animals Technology Co., Ltd. provides, conformity certification number: SCXK (capital) 2002-0003, body weight 18-22g.Laboratory room temperature 20-22 ℃, relative humidity 40%～60%, the ventilator ventilation, lamp 12h/ day, raise in cages, 10 in every cage, per three days cleaning cage houses are once.
Get normal mouse, get brain after the execution, add physiological saline do homogenate (with the brain ratio be 5: 1).4 ℃ of refrigerators left standstill 5 minutes, got the even muddy liquid in top.Every pipe adds cerebral tissue liquid 150uL, adds different concns soup 50ul, and 37 ℃ of water-baths were hatched 30 fens.Add 10%SDS 0.1ml successively, 50% Glacial acetic acid thiobarbituricacid liquid 0.5ml and 1% hydrochloric acid solution 2ml.Boiling water bath 15 minutes takes out back cold water and put 10 minutes, and 1500 left the heart 15 minutes, gets supernatant and surveys the absorbance A value in the 532nm place.Do three multiple pipes for every group.Calculate inhibiting rate=[(control group A-administration group A)/control group A * 100%].
The gained data are through the EXCEL software processes.T check between group.
This test Ananasoside A and Ananasoside B administration final concentration are respectively 1 * 10 -4G/ml, 1 * 10 -5G/ml, 1 * 10 -6G/ml.
This test is an experiment in vitro.This test blank is an equal-volume physiological saline. the positive drug contrast is for vitamin-E, available from Sigma company.The experiment final concentration is 1 * 10 -5G/ml.This testing data is all with the Excel software processes.
Table 5 Ananasoside A, and the external restraining effect that brain MDA is generated of B (x ± s)
Grouping Medicine final concentration (g/ml) Umol/g
Physiological saline vitamin C Ananasoside A Ananasoside A Ananasoside A Ananasoside B Ananasoside B Ananasoside B 1×10 -3 1×10 -4 1×10 -5 1×10 -6 1×10 -4 1×10 -5 1×10 -6 104.43±9.95 42.38±1.66** 48.72±2.64** 57.0±6.17** 68.6±3.88** 50.72±3.08** 60.3±7.53** 68.31±1.15**
Compare * P＜0.05, * * P＜0.01 with the physiological saline group.n＝3
This experimental result shows, the external effect that has inhibition strongly to lack sugared anoxic cerebral tissue MDA generation of Ananasoside A and Ananasoside B, and minimal effective concentration is 1 * 10 -6G/ml.The prompting Ananasoside A, B has certain oxidation resistant effect.

Claims (3)

1. pineapple anhydride compound, its chemical structure of general formula is as follows:
Wherein:
Ananasoside A: R1=O-β-D-xyl R2=OH R3=H, H R4=OH
Ananasoside B: R1=O-β-D-glu (6 → 1) glu R2=H, H R3=OH R4=H, H
2. the application of pineapple anhydride compound in the medicine of endoperoxide rising of preparation treatment body and the disease that causes thus according to claim 1.
3. the application of pineapple anhydride compound in the former impaired medicine of preparation treatment cerebral ischemia and the cranial nerve that causes thus according to claim 1.
CN 200410009056 2004-04-29 2004-04-29 Pineapple anhydride compound and its use Expired - Fee Related CN1258536C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 200410009056 CN1258536C (en) 2004-04-29 2004-04-29 Pineapple anhydride compound and its use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 200410009056 CN1258536C (en) 2004-04-29 2004-04-29 Pineapple anhydride compound and its use

Publications (2)

Publication Number Publication Date
CN1569883A CN1569883A (en) 2005-01-26
CN1258536C true CN1258536C (en) 2006-06-07

Family

ID=34477786

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 200410009056 Expired - Fee Related CN1258536C (en) 2004-04-29 2004-04-29 Pineapple anhydride compound and its use

Country Status (1)

Country Link
CN (1) CN1258536C (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101648980B (en) * 2009-08-28 2013-01-30 广东轻工职业技术学院 Method for combined preparation of pineapple polyphenol and juice by taking pineapple peel as main material and application thereof
CN103224545B (en) * 2013-05-15 2014-09-17 江南大学 Sulfur-containing compound with nerve protection effect and application thereof

Also Published As

Publication number Publication date
CN1569883A (en) 2005-01-26

Similar Documents

Publication Publication Date Title
CN108042627B (en) Composition for treating hyperuricemia and preparation method and application thereof
CN1224383C (en) Blood sugar reducing compound
CN103980197B (en) Spina Date Seed alkaloid monomer composition acid Lee alkali and preparation method thereof and application
CN1682842A (en) Chinese medicine composition for diminishing-inflammation and detoxication and its preparing method and use
CN1806821A (en) Rhinitis-treating medicine
CN100528214C (en) Capsule for treating epilepsia and its preparing method
CN1258536C (en) Pineapple anhydride compound and its use
CN101396373B (en) Cinobufacini extract and preparation method thereof
CN101406527B (en) Method for preparing salts of Corydalis ambigua total alkaloid and use thereof as medicament for treating cardiovascular disease
CN105012356B (en) Purposes of the ganoderic acid A in depression
CN1246326C (en) Pineapple flavonoid glycoside compound and its use
CN1943570A (en) Use of opc in preparing medicine for treating and preventing senile dementia
CN1687092A (en) General glycoside extractive of xanthium and preparation method
CN106074643B (en) Application of acanthopanax giraldii harms leaf and extract thereof in preparing anti-fatigue medicine or health food
CN1698717A (en) Chinese medicinal compound fat emulsion injection and its preparation method
CN1778324A (en) Effective part of nightshadeleaf ironweed for antiscolic medicines and its preparation and use
CN113425739A (en) Lily and rehmannia compound polysaccharide with anxiolytic and antidepressant effects and application thereof
CN1654038A (en) Buccal tablet of tea polyphenol for preventing and treating colds and resisting inflammation and preparation thereof
CN1283391A (en) Extracted liquor for disinfection
CN1316985C (en) Novel use of extractive from sapan wood
Mukherjee et al. Effectiveness of Brahmi in various illnesses: Review paper
CN104130232B (en) The method of purification of a kind of EGCG and the EGCG of acquisition and pharmaceutical composition
CN1931208A (en) Application of common goldenrod herb in preparing medicine for preventing and treating H5N1 bird flu and influenza
CN1803155A (en) Medicine for curing rhinitis
CN100434085C (en) Process for removing toxic component from oleum fructus bruceae

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee